| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8524733 | TEVA | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Apr, 2031
(6 years from now) | |
| US9550780 | TEVA | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8524733 (Pediatric) | TEVA | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Oct, 2031
(7 years from now) | |
|
US9550780 (Pediatric) | TEVA | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(9 years from now) | |
| US11357772 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(11 years from now) | |
| US11446291 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(11 years from now) | |
| US11648244 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(11 years from now) | |
| US10959996 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(11 years from now) | |
| US11564917 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(11 years from now) | |
|
US11357772 (Pediatric) | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
|
US11648244 (Pediatric) | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
|
US10959996 (Pediatric) | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
|
US11564917 (Pediatric) | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
|
US11446291 (Pediatric) | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
| US11179386 | TEVA | Analogs of deutetrabenazine, their preparation and use |
Mar, 2038
(13 years from now) | |
| US11813232 | TEVA | Analogs of deutetrabenazine, their preparation and use |
Mar, 2038
(13 years from now) | |
|
US11179386 (Pediatric) | TEVA | Analogs of deutetrabenazine, their preparation and use |
Sep, 2038
(14 years from now) | |
|
US11813232 (Pediatric) | TEVA | Analogs of deutetrabenazine, their preparation and use |
Sep, 2038
(14 years from now) | |
| US11311488 | TEVA | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |
Jun, 2041
(17 years from now) | |
Austedo Xr is owned by Teva.
Austedo Xr contains Deutetrabenazine.
Austedo Xr has a total of 19 drug patents out of which 0 drug patents have expired.
Austedo Xr was authorised for market use on 17 February, 2023.
Austedo Xr is available in tablet, extended release;oral dosage forms.
Austedo Xr can be used as a method of treating huntington's chorea, treatment of tardive dyskinesia.
The generics of Austedo Xr are possible to be released after 10 June, 2041.
Drugs and Companies using DEUTETRABENAZINE ingredient
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea
Dosage: TABLET, EXTENDED RELEASE;ORAL
AUSTEDO XR family patents
